VIVUS, Inc. (VVUS) Pops as Larger Qsymia Retail Presence Expected Soon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Brean Capital Maintains Sell of Vivus (VVUS), Notes Slower April Growth
May 8, 2013 3:06 PM EDTBrean Capital today maintained a Sell rating on Vivus (NASDAQ: VVUS) with a price target of $6.00. Vivus recently reported Q1 results.
Commenting, analyst Jonathan Aschoff said, "A total of 59,000 prescriptions were sold in 1Q13, of which 21,000 were shipped under the free trial offer,... More
VIVUS, Inc. (VVUS) Posts Q1 Loss of 53c/Share
May 8, 2013 7:31 AM EDTVIVUS, Inc. (NASDAQ: VVUS) reported Q1 EPS of ($0.53), $0.02 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $5.22 million.
For earnings history and earnings-related data on VIVUS, Inc. (VVUS) click here.... More
